Tenna Vesterman Henriksen

Tenna Vesterman Henriksen

Auto-generated profile, based on publicly available information

Tenna Vesterman Henriksen

Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2020 in Acta Oncologica
Verified
Journal Article
Closed access
JNJesper Nors
Jesper Nors
THTenna Vesterman Henriksen
Tenna Vesterman Henriksen
KGKåre Andersson Gotschalck
Kåre Andersson Gotschalck
TJTherese Juul
Therese Juul
JSJes Søgaard
Jes Søgaard
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
(2020). IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer – intervention trial 2. Study protocol. Acta Oncologica. Ahead of Print.

29 April 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JMJorge Martín-Arana
Jorge Martín-Arana
FGFrancisco Gimeno-Valiente
Francisco Gimeno-Valiente
THTenna Vesterman Henriksen
Tenna Vesterman Henriksen
BGBlanca García-Micó
Blanca García-Micó
BMBelén Martínez-Castedo
Belén Martínez-Castedo
NTNoelia Tarazona
Noelia Tarazona
In stage 2–3 colon cancer (CC), postsurgery circulating tumor DNA (ctDNA) assessment is crucial for guiding adjuvant chemotherapy (ACT) decisions. While existing assays detect ctDNA and help identify high-risk persons with CC for recurrence, their limited sensitivity after surgery poses challenges in deciding on ACT. Additionally, a substantial portion of persons with CC fail to clear ctDNA after ACT, leading to recurrence. In this study, we performed whole-exome sequencing (WES) of ctDNA at different time points in participants with relapsed CC in two independent cohorts, alongside transcriptomic and proteomic analyses of metastases, to enhance comprehension of progression mechanisms. A plasma WES-based tumor-agnostic assay demonstrated higher sensitivity in detecting minimal residual disease (MRD) compared to current assays. Immune evasion appears to be the primary driver of progression in the localized CC setting, indicating the potential efficacy of immunotherapy for microsatellite stability in persons with CC. Organoid modeling further supports the promising potential of targeted therapy in eradicating MRD, surpassing conventional treatments.

20 January 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
THTenna V Henriksen
Tenna V Henriksen
NTNoelia Tarazona
Noelia Tarazona
TRThomas Reinert
Thomas Reinert
JCJuan Antonio Carbonell-Asins
Juan Antonio Carbonell-Asins
DRDerrick Renner
Derrick Renner
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
11Background: Timely detection of recurrence, as well as identification of patients at high risk of recurrence after surgery and after completion of adjuvant therapy, are major challenges in the tr...

20 February 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
THTenna V. Henriksen
Tenna V. Henriksen
CDChristina Demuth
Christina Demuth
AFAmanda Frydendahl
Amanda Frydendahl
JNJesper Nors
Jesper Nors
MNMarijana Nesic
Marijana Nesic
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
Purpose: Multiple clinical trials are investigating ctDNA to guide adjuvant chemotherapy (ACT) in colorectal cancer. Timely ACT initiation necessitates early ctDNA testing, but the impact of postoperative cell-free DNA (cfDNA) and ctDNA dynamics remains unclear, particularly with cost-reducing input caps employed in some assays. This study investigates ctDNA detection at day 14 versus day 30, comparing whole-sample analysis with capping the cfDNA input, and evaluates single and dual timepoint assessments for ACT allocation. Experimental Design: From 2019 to 2023, 611 patients with stage I to III colorectal cancer were enrolled. Blood was collected preoperatively and postoperatively on ∼day 14 and ∼day 30. The cfDNA levels were assessed using digital PCR, and ctDNA was assessed using tumor-informed digital PCR or targeted sequencing analyzing all cfDNA from 8 mL of plasma. Results: Despite elevated cfDNA in 85% of day 14 samples, performance was comparable between the two timepoints (sensitivity, 31% vs. 32% and specificity, both 98%). A 50-ng cfDNA input cap reduced ctDNA detection probability, affecting 78% of day 14 samples and 65% of day 30 samples. At both timepoints, ctDNA detection was prognostic of recurrence (day 14; HR, 9.0, 95% confidence interval, 5.5–14.8 and day 30: HR, 12.5, 95% confidence interval, 7.6–20.4). In 74% of ctDNA-positive recurrence patients, both samples had ctDNA detected. An increase in the ctDNA level from day 14 to day 30 was associated with a shorter time to recurrence (Pearson R = −0.63, P = 0.003). Combining the timepoints would increase sensitivity (36%) and allow earlier ACT start in 80% of patients. Conclusions: Early ctDNA sampling is feasible and highly prognostic. Supplemental later testing may improve sensitivity while allowing early ACT initiation for most ctDNA-positive patients.

25 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJens Bo Koudahl Conrad
Jens Bo Koudahl Conrad
THTenna Vesterman Henriksen
Tenna Vesterman Henriksen
JNJesper Nors
Jesper Nors
MRMads Heilskov Rasmussen
Mads Heilskov Rasmussen
MØMai-Britt Worm Ørntoft
Mai-Britt Worm Ørntoft
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
Circulating tumor DNA (ctDNA) has high clinical potential in early cancer detection. The renal system and the liver are involved in clearing circulating cell free DNA (cfDNA) from the blood. Recent studies on mice show that inhibiting the liver’s ability to clear cfDNA results in elevated ctDNA levels in blood samples. Emphasizing the need for studies in humans exploring if markers of renal and liver function are associated with cfDNA and ctDNA levels in the blood. The present study investigates if cfDNA level, ctDNA level and ctDNA detection is affected in colorectal cancer (CRC) patients with clinical biomarkers indicative of low renal and liver function. We requisitioned standard laboratory tests of renal and liver function, measured within thirty days of curative intended surgery from 846 stage I-III CRC patients. For each patient, matching preoperative cfDNA and ctDNA data was available. We investigated the correlation between impaired renal and liver function and cfDNA level, ctDNA level, and ctDNA detection. The findings revealed that variation in renal and liver function in stage I-III CRC patients did not affect cfDNA level, ctDNA level, or ctDNA detection and that ctDNA test results remain stable over a wide range of renal and liver biomarker results.

21 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LOLudvig Renbo Olsen
Ludvig Renbo Olsen
DODenis Odinokov
Denis Odinokov
JHJakob Qvortrup Holsting
Jakob Qvortrup Holsting
KKKaroline Kondrup
Karoline Kondrup
LILaura Iisager
Laura Iisager
SBSøren Besenbacher
Søren Besenbacher
The fragmentation patterns of whole genome sequenced cell-free DNA are promising features for tumor-agnostic cancer detection. However, systematic biases challenge their cross-cohort generalization. We introduce LIONHEART, an open source cancer detection method specifically optimized to generalize across datasets. The method correlates bias-corrected cfDNA fragment coverage across the genome with the locations of accessible chromatin regions from 898 cell and tissue type features. We use these correlations to detect changes in the cell-free DNA cell type composition caused by cancer. We test LIONHEART on nine datasets and fourteen cancer types (1106 non-cancer controls, 1449 cancers) obtained from different studies and show that it can distinguish cancer samples from non-cancer controls across cohorts with ROC AUC scores ranging from 0.62-0.95 (mean = 0.83, std = 0.12). We further validate the method on an external dataset, achieving a ROC AUC of 0.917.